WANG Ning;CONG Nan;LIU Xuan;CHEN Si;YANG Jiao-jiao;LIU Nian;DONG Yu-xi;ZHAO Pi-wen;School of Life Sciences,Beijing University of Chinese Medicine;Department of Gynecology,the First Affiliated Hospital of Jinzhou Medical University;School of Chinese Materia Medica,Beijing University of Chinese Medicine;This study investigated the molecular mechanism by which icariin regulates mitophagy via the estrogen receptor α(ERα)-mediated silencing of the regulatory protein 1(SIRT1)/forkhead box protein O3a(FOXO3a) pathway and its downstream PTEN-induced kinase 1(PINK1)/Parkin signaling axis, thereby influencing bone metabolism and osteoblast differentiation to ameliorate postmenopausal osteoporosis(PMOP). Network pharmacology and molecular docking were initially employed to identify key targets of icariin and potential signaling pathways related to PMOP, followed by validation of icariin′s binding affinity to these targets. For in vivo experiments, 36 female C57BL/6J mice were randomly divided into six groups: sham-operation, model, estradiol(E_2)-treated, and low-, medium-and high-dose icariin-treated groups, respectively. In the sham operation group, some fat pads around the ovaries were removed from the mice, while the PMOP models were established through castration surgery in other groups. The drug administration groups were respectively given estradiol or icariin for continuous intervention for 8 weeks. Estrus cycle changes were monitored, while serum hormone and bone metabolism levels were measured by ELISA. Meanwhile, the femoral microstructure was evaluated using Micro-CT and HE staining, and bone anabolism was assessed by Western blot, Masson staining, and Goldner staining, respectively. In addition, mitophagy and expression of related proteins were examined by Western blot and transmission electron microscopy, while SIRT1/FOXO3a pathway proteins were analyzed by Western blot. For in vitro experiments, MC3T3-E1 cells were divided into control(osteogenic induction) and icariin-treated groups(low, medium, and high doses), with additional ERα antagonist and SIRT1 inhibitor interventions. Osteogenic differentiation and extracellular matrix mineralization were evaluated using ALP staining, alizarin red staining, and Western blot. Mitophagy and expression of related proteins were examined by Western blot and immunofluorescence detection, while the expression of proteins related to SIRT1/FOXO3a pathway was detected by Western blot. The results of network pharmacology analysis showed that SIRT1/FOXO3a was identified as a critical pathway to regulate PMOP, with icariin exhibiting high binding affinity to ERα. The results of in vivo experiments showed that compared to the sham operation group, the model group exhibited disrupted estrous cycles along with significantly decreased serum E_2 and procollagen type Ⅰ N-terminal propeptide(P1NP) levels, while follicle-stimulating hormone(FSH), luteinizing hormone(LH), and C-terminal telopeptide of type Ⅰ collagen(CTX-1) levels were markedly elevated, indicating successful establishment of the PMOP model. Following icariin intervention, the treatment group showed significantly increased serum P1NP levels and decreased CTX-1 levels compared to the model group. Meanwhile, icariin improved femoral microstructure, increased the areas of collagen deposition and mineralized bone matrix, and upregulated osteogenic-specific proteins, such as osteopontin(OPN) and osteoprotegerin(OPG). Icariin promoted the formation of autophagolysosome-like structures in osteoblasts. It inhibited the expression of autophagy-related protein P62 while upregulating mitophagy-related proteins PINK1, Parkin, microtubule-associated protein 1A/1B light chain 3A(LC3Ⅱ/LC3Ⅰ) and Beclin1, as well as the key pathway proteins SIRT1 and FOXO3a. The results of in vitro experiments demonstrated that icariin upregulated the expression of OPN and OPG, while promoting osteogenic differentiation and extracellular matrix mineralization. It downregulated P62 protein expression while enhancing the expression of PINK1, Parkin, LC3Ⅱ/LC3Ⅰ and Beclin1. Additionally, icariin increased the co-localization fluorescence intensity of LC3 with MitoTracker. Upon the addition of the ERα antagonist, the expression levels of SIRT1, FOXO3a, PINK1, and Parkin were significantly reduced, accompanied by weakened co-localization fluorescence intensity. When the SIRT1 inhibitor was introduced, the expression of acetylated FOXO3a increased, while the expression of PINK1, Parkin, and FOXO3a markedly decreased, along with diminished co-localization fluorescence intensity. In summary, icariin ameliorates PMOP by enhancing PINK1/Parkin-dependent mitophagy via the ERα-SIRT1/FOXO3a pathway, thereby regulating bone metabolism and promoting bone remodeling.
2026 04 v.51 [Abstract][OnlineView][Download 1352K]